Dr. Bin Shi （石斌）joins Amgen Asia R&D Center in Sept., 2016 serving as Head of External R&D and Licensing to leverage wide external scientific and technology expertise in China and Asian Pacific areas to advance and complement Amgen’s global internal effort in discovery of breakthrough medicines. Before that, Bin has been working in the pharmaceutical industries in US for more than 18 years, overseeing anti-cancer, anti-viral and vaccine drug discovery and development. She is a Research Fellow and Associate Principle Scientist in Pharmacology Department at Merck West Point, PA. She has been an active member of AACR (American Association of Cancer Research) since 2006 and a member of NSH (National Society of Histotechnology).  Bin has published more than 40 papers, abstracts and patents in reputed journals including JBC, Cancer Research etc, serving as the first and corresponding author, serving as an invited reviewer for eight peer reviewed journals, editorial board member and an invited speaker at several conferences.  She is also actively involved in community services, including Lead of of LINK at Merck to leverage internal networking, knowledge and communication, and Liaison of LINK and Merck Polytechnology training Institution (MPI).  Bin is a lifetime SAPA member, and serves in the senior leadership team (SLT) of SAPA-GP with increased responsibility: Executive Council, General Secretary, VP of Public Affairs, Communication and Outreach, President-elect (2015-2016) and President (2016-2017).  Most recently Bin is elected as President-elect of SAPA-China (present-2021). Bin completed her Ph.D. at Thomas Jefferson University in Philadelphia, her Master of Science degree at State University of New York (SUNY) in Syracuse, and her Bachelor of Science degree at Nankai University in Tianjin China.